Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, its Novel Candidate for Inflammatory Bowel Disease
Author: admintech | Filed under: World
This entry was posted
on Tuesday, July 14th, 2020 at 7:09 am and is filed under World.
You can follow any responses to this entry through the RSS 2.0 feed.
Both comments and pings are currently closed.